209.03 USD
↗ 9.88 (4.96%)AT CLOSE (11:59 AM EDT)
Biogen Inc. Common Stock
BIIBNASDAQ • USD
208.84
↘ 0.19 (0.09%)
POST MARKET (AS OF 07:58 PM EDT)
Post Market
AS OF 07:58 PM EDT
208.84
↘ 0.19 (0.09%)
Market: CLOSED
Biogen Inc. Common Stock (BIIB) is currently trading at $209.13. Technicals currently rate "Strong Buy" while our fundamental analysis reads "Neutral". Notable factors include a robust Altman Z-Score, a bullish Golden Cross on the moving averages and bullish moving average alignment. The stock looks compelling on valuation, with multiples below sector averages across P/E, P/B, and EV/EBITDA.
Technical & fundamental data as of Jul 13, 2026.
Open?$199.33
High?$210.87
Low?$197.74
Prev. Close?$199.15
Volume?2.3M
Avg. Volume?1.2M
VWAP?$206.35
Rel. Volume?1.88x
Bid / Ask
Bid?$197.39 × 100
Ask?$221.12 × 100
Spread?$23.73
Midpoint?$209.26
Valuation & Ratios
Market Cap?29.4B
Shares Out?147.6M
Float?147.4M
Float %?99.8%
P/E Ratio?21.43
P/B Ratio?1.58
EPS?$9.29
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
Employees
7.5K
Market Cap
29.4B
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
Listed
1991-09-17
Address
225 BINNEY STREET
CAMBRIDGE, MA 02142
Phone: (781) 464-2000
CAMBRIDGE, MA 02142
Phone: (781) 464-2000
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+2/3)
Medium-Term (Wave)?▲ Bullish(+1/3)
Short-Term (Ripple)?▲ Bullish(+3/3)
MA Alignment?Golden Alignment
Full Technical Analysis →Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?40
Z-Score?82
Momentum?50
Short Sent.?64
Piotroski F-Score?4/9Mixed
Altman Z-Score?3.42Safe
Confidence?73%Moderate
Short InterestModerate
Short % of Float?3.88%Low
Short Interest?5.7M
Days to Cover?4.1
Free Float147.4M
Avg Daily Volume1.4M
Settlement Date2026-06-30
Financial Health
Current Ratio?3.06Strong
Quick Ratio?2.41Strong
Cash Ratio?1.13Strong
Debt/Equity?0.34Low
ValuationATTRACTIVELY VALUEDvs 10 peers + S&P 500
Score89/100
P/E?21.4FAIR▾
Peers71
S&P60
P/B?1.58CHEAP▾
Peers90
S&P85
P/S?2.96CHEAP▾
Peers90
S&P51
P/FCF?12.1CHEAP▾
Peers86
S&P83
EV/EBITDA?11.8CHEAP▾
Peers86
S&P70
EV/Sales?3.25FAIR▾
Peers80
S&P57
Returns & Efficiency
ROE?7.4%FAIR▾
Peers17
S&P24
ROA?4.7%FAIR▾
Peers29
S&P42
Cash Flow & Enterprise
FCF?$2.4B
Enterprise Value?$32.3B
Fundamentals ratios updated end of day